Background: Guideline recommendations for the management of patients with ST-elevation myocardial infarction (STEMI) are mainly based on data from randomized clinical trials.
Introduction
Despite significant improvements in medical and interventional treatments that have occurred in recent years, ST-segment elevation myocardial infarction (STEMI) remains a leading cause of death in the world. 1 Most of the scientific evidence that supports the treatment of patients with STEMI comes from randomized clinical trials (RCT). However, patients included in RCTs are not representative of those seen in the daily practice, who are generally older, with more comorbidities and tend to present higher cardiovascular event rates.
2,3 The short-term mortality of STEMI patients included in recent RCTs has been reported to be below 5%. 4, 5 However, contemporary real-world registries show higher rates even in developed countries in Europe. [6] [7] [8] [9] [10] In the present study, we sought to investigate temporal trends in the baseline characteristics, medical and invasive treatments 
Methods

Patients
This was a prospective cohort study which consecutively included all patients with STEMI who presented at the Instituto de Cardiologia do Rio Grande do Sul, Fundação Universitária de Cardiologia, Porto Alegre, Brazil, from January 2010 to December 2013. Our facility is a tertiary referral center, and its catheterization laboratory works 24 hours a day, seven days a week, with at least one member of the health team at the facility.
The inclusion criterion was STEMI in the first 12 hours. STEMI was defined as typical chest pain at rest associated with ST-segment elevation of at least 1mm in two contiguous leads in the frontal plane or 2 mm in the horizontal plane, or typical pain at rest in patients with a new, or presumably new, left bundle-branch block. The exclusion criteria were time from onset of symptoms to hospital arrival above 12 hours, age less than 18 years or refusal to participate.
Primary Percutaneous Coronary Intervention Procedures
The medications used in the patient's initial care follow the routines of our institution: a bolus dose of acetylsalicylic acid (300 mg) and clopidogrel (300 to 600 mg) was administered in the emergency room immediately after patient arrival. Anticoagulant therapy (heparin 70-100 U/Kg) was administered in the emergency room at the discretion of the attending physician. For those not receiving heparin in the emergency room, it was given in the catheterization laboratory if the patient would undergo primary percutaneous coronary intervention (pPCI).
After conventional coronary angiography, pPCI was performed as described elsewhere.
1 Aspects related to the procedure were left at the operators' discretion. Coronary flow before and after the procedures was assessed and described according to the Thrombolysis in Myocardial Infarction (TIMI) criteria. 11 Myocardial blush was assessed as described elsewhere.
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Data Collection, Outcomes and Follow-up
All patients were interviewed on hospital admission, and visited daily during the in-hospital period by one of the investigators. All-cause mortality and major cardiovascular events (MACEs) were assessed and registered by one of the study investigators. MACEs were defined as a combination of all-cause mortality, new myocardial infarction (MI) or stroke. New MI was defined as recurrent chest pain with new elevation of serum biomarkers, after the initial decline of the natural curve, with ST-segment elevation or new Q waves. Stroke was defined as a new, sudden-onset focal neurological deficit, of presumably cerebrovascular cause, irreversible (or resulting in death) within 24 hours and not secondary to any other readily identifiable cause. Major bleeding was defined according to the TIMI criteria.
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Statistical Analysis
Statistical analysis was performed using SPSS for Windows 22.0. Results are expressed as mean ± SD or absolute and relative frequencies as appropriate. Variables with a non-normal distribution are presented as median and interquartile range. This was a consecutive cohort study, and a sample size calculation was not previously performed. Statistical significance was defined as a two-tailed p-value < 0.05.
For categorical variables, the chi square test for trend was used. For continuous variables, the ANOVA and Tukey test were used for multiple comparisons in the case of normal distribution and the Kruskal-Wallis´s test for non-normal variables. Multivariate logistic regression was used to assess independent predictors of 30-day MACE.
Results
Patients
In the study period, 1973 patients were included; pPCI was performed in 1884 of them (95.5%) and cardiac surgery in 4 (0.2%). The remaining 85 patients (4.3%) received medical treatment, either because there was no significant coronary stenosis or because only a minor branch was occluded and considered to be unsuitable for intervention. No thrombolysis was performed at our hospital, but 38 patients had received thrombolytics (2%) prior to transfer from another institution.
Clinical Characteristics
The percentage of patients diagnosed with diabetes mellitus significantly increased over the years, and the 
Angiographic and Procedural Features
The lesion length increased significantly over the years ( Table 2 ). There was a significant increase in the use of the radial approach, which was 9% in 2010 and increased to 66% in 2013. The rates of adjunctive aspiration thrombectomy declined significantly, and the use of Table 3 shows aspects of the medical treatment in the first 24 hours of hospitalization according to the year of STEMI. Aspirin and clopidogrel were used in virtually all patients. The use of a 600 mg clopidogrel bolus increased over the years, with 93% of patients receiving this higher dosing scheme in 2013. The use of adjunctive IIb/IIIa glycoprotein in the catheterization laboratory also significantly increased, as well as that of an upstream heparin bolus (in the emergency room, before catheterization laboratory arrival). The use of statin remained stable in almost 4 out of 5 patients, but that of beta-blockers, angiotensin-converting enzyme inhibitors and nitrates significantly decreased. To better understand the reasons leading to the progressive lower use of betablockers over the years, we assessed the baseline risk profile of these patients. The mean TIMI risk score of patients receiving beta-blockers decreased significantly over the years (2010= 3.23±2.04; 2011=3.33±2.08; 2012=1.92±2.20 and 2013=1.86±2.02; p=.008).
Medical Treatment
Outcomes
The overall rates of combined and individual 30-day adverse cardiovascular events in this population were as follows: MACE=13%, death=8.5%, MI=4.2%, stroke=0.9%, stent thrombosis=2.3%, and major bleeding=2.4%. Figure 1 shows the rates of cardiovascular outcomes over the study period. Major cardiovascular events decreased significantly from 17.4% in 2010 to 9.5% in 2013 (p < 0.05). Mortality also decreased from 8.8% in 2010 to 7.1% in 2013, but this difference did not reach statistical significance. MI (7.3% vs 2.9%), urgent revascularization procedures (3.9% vs 2.4%) and stent thrombosis (3.8% vs 2.1%) also decreased from 2010 to 2013, but these differences were also not statistically significant. Stroke and bleeding rates remained relatively stable. The association between major bleeding and access site to perform pPCI was assessed. The rate of major bleeding in patients undergoing pPCI via the radial approach was 0.9%, and 3.3% when pPCI was performed via the femoral approach (p < 0.001). Patients who presented with major bleeding had significantly higher rates of 30-day MACE (42% vs 11%; p < 0.001) and mortality (29% vs 7%; p < 0.001) than those who did not bleed.
Patients who received upstream heparin had a better rate of blush-3 grades post procedure (72% vs 64%; p < 0.01), and lower rates of MACE (10.9% vs 17.3%; p < 0.001) and death (7.4% vs 11.5%; p=0.004) than those who received the first heparin bolus only in the catheterization laboratory. Table 4 shows multivariate analysis for 30-day MACE. Several baseline variables such as age, Killip III/IV class and atrioventricular block were associated with MACE, as shown in previous studies. Interestingly, dyslipidemia was a protective factor for MACE. Regarding pharmacological treatment, the use of an upstream bolus of heparin in the emergency room and of beta-blockers were also significantly associated with lower MACE, but a 600 mg bolus of clopidogrel was not. In relation to interventional aspects, the radial approach to perform pPCI and less residual stenosis after stent implantation were associated with lower MACE rates.
Multivariate Analysis
Discussion
The decline in cardiovascular events reported in the present study can be considered clinically significant and meaningful, since 30-day MACE rates were almost halved in this four-year period. This important reduction cannot be explained by the selection of lower risk patients over the years, since all patients presenting to our institution with STEMI were consecutively included during the study. Additionally, the mean TIMI risk score for STEMI and other high-risk baseline characteristics remained relatively stable over time, and the frequency of diabetes mellitus increased. Instead, independent predictors of lower MACE rates were the use of the radial
Original Article approach, of beta-blockers, upstream heparin bolus, and several other baseline variables traditionally associated with cardiovascular events in previous studies. The rates of short-term cardiovascular events reported in the present study compare favorably with recent reports in patients representative of the daily clinical practice in developed countries. [6] [7] [8] [9] [10] However, the decline in MACE rates described in our study is in contrast to that of a large nationwide registry in Germany demonstrating no improvement in outcomes from 2005 to 2009. 6 During the study period, we observed a remarkable increase in the use of the radial approach, which was 9% in 2010 and increased to 66% in 2013. The use of the radial approach was independently associated with a 47% lowering of 30-day MACE, as well as with significantly lower rates of major bleeding in comparison to the femoral approach. Patients who experienced a major bleeding had significantly higher rates of 30-day MACE, and this probably explains the benefit of the radial approach in this cohort.
14 Despite several studies demonstrating significant benefits of the radial approach in patients with STEMI, [14] [15] [16] it has been infrequently adopted in the clinical practice in some countries. 17 One of the reasons is the learning curve to perform pPCI through the arm, 18 and also concerns that it would increase the door-to-balloon time in patients with STEMI. In the present study, we report the opposite, i.e., the use of the radial approach increased over the years, and the door-to-balloon time significantly decreased. Anticoagulant use immediately on patient arrival at the emergency room as compared to its use in the catheterization laboratory increased significantly over the study period, and 91% of the patients were treated with this approach in 2013. Bivalirudin is not approved for clinical use in Brazil, and heparin is the most frequently used anticoagulant in most centers. Among patients treated with a strategy of upstream heparin, there was a higher frequency of post-procedural grade-3 blush, lower mortality rate, and a 36% lower MACE rate by multivariate analysis. The recent European guidelines on STEMI recommend unfractionated heparin as one of the reasonable options for intravenous anticoagulant therapy in the setting of STEMI, 1 but there is no mention regarding the timing of administration, whether upstream or in the catheterization laboratory. The influence of upstream heparin on cardiovascular outcomes in STEMI patients has been evaluated by several studies, [19] [20] [21] [22] [23] which have shown different results. Like ours, other institutions have adopted the use of upstream heparin in STEMI patients. 24 Since a proper sized randomized clinical trial is not available, the observational data presented here should reinforce the notion that upstream heparin is at least safe, and probably beneficial, in contemporary STEMI patients treated mainly via the radial approach.
Finally, we believe that one important characteristic of the present study is the inclusion of all patients who presented with STEMI in our institution in the study period, with no exclusions. It has been shown that the exclusion of even a small number of patients from a registry in the setting of STEMI can cause a significant selection bias, since the patients excluded are generally those with more comorbidities and higher event rates. 25, 26 The limitations of this study include its observational nature, which preclude definitive conclusions regarding the effect of therapies on outcomes even after performance of a multivariate analysis. Most of the patients included in this cohort have received medical and interventional treatment according to the policies of the public health system in Brazil, which do not reimburse drugeluting stents, prasugrel, ticagrelor or bivalirudin. This may limit extrapolation of the results, although patient characteristics and outcomes reported here are comparable to those of several others large reference centers over the world. This prospective registry started in 2010, and the collection of clinical data and the knowledge of the existence of an initiative to evaluate the clinical practice may have influenced medical decisions by the attending physicians. The angiographic results were not independently evaluated by a core angiographic laboratory, a limitation that is also shared by several other contemporary registries of pPCI patients. The 30-day follow-up evaluation is short and may be not enough to precisely identify the impact of the different studied factors on cardiovascular outcomes. However, 30-day outcomes have traditionally been considered as an important and relevant clinical outcome in STEMI patients by several previous studies.
In conclusion, we showed that baseline characteristics of patients with STEMI presenting to a tertiary referral center in interventional cardiology remained stable over a four-year period, except for the frequency of diabetes mellitus, which increased significantly. Medical and interventional treatments significantly improved, and short-term adverse cardiovascular outcomes significantly decreased. Predictors of better outcomes were baseline characteristics, upstream heparin use and the radial approach to perform primary PCI.
